Systematic review and meta-analysis demonstrates preclinical efficacy of mesenchymal stem cells in acute respiratory distress syndrome, highlighting the need for definitive safety evaluations.
Mesenchymal stem cells (MSC) therapy for acute respiratory distress syndrome (ARDS) represents a burgeoning treatment approach, supported by numerous preclinical studies confirming its efficacy. Our study aims to provide a comprehensive evaluation of both the safety and effectiveness of MSC.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: